ARS Pharmaceuticals (SPRY) News Today → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free SPRY Stock Alerts $8.26 -0.24 (-2.82%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up to $8.21marketbeat.com - April 23 at 12:30 PMSarina Tanimoto Sells 100,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stockamericanbankingnews.com - April 19 at 4:34 AMARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 3.4% on Insider Sellingamericanbankingnews.com - April 19 at 1:36 AMArs Pharmaceuticals CEO sells over $928k in company stockinvesting.com - April 19 at 1:04 AMARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 3.4% Following Insider Sellingmarketbeat.com - April 18 at 12:17 PMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sarina Tanimoto Sells 100,000 Sharesinsidertrades.com - April 18 at 6:16 AMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Short Interest Up 29.4% in Marchamericanbankingnews.com - April 15 at 5:40 AMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Short Interest Updatemarketbeat.com - April 13 at 7:26 PMArs Pharmaceuticals CEO sells shares worth over $927kinvesting.com - April 12 at 2:42 AMArs pharmaceuticals exec sells shares worth over $927kinvesting.com - April 12 at 2:42 AMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Richard E. Lowenthal Sells 100,000 Sharesinsidertrades.com - April 11 at 6:37 AMARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 6.8% marketbeat.com - April 9 at 11:46 AMARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 4.1%marketbeat.com - April 5 at 12:51 PMARS Pharma Submits Addl. Data In Response To FDA's CRL For Neffymarkets.businessinsider.com - April 3 at 11:54 AMHere's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situationfinance.yahoo.com - April 3 at 11:54 AMARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)globenewswire.com - April 3 at 9:01 AMARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 6.1%marketbeat.com - April 1 at 3:48 PMHuge Insider Buying From Buffett, an NFL Team Owner, a New CEO247wallst.com - March 31 at 8:55 AMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Purchases $3,964,656.00 in Stockinsidertrades.com - March 28 at 7:54 AMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Ra Capital Management, L.P. Buys 437,600 Sharesmarketbeat.com - March 27 at 9:28 PMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $21,133.86 in Stockinsidertrades.com - March 27 at 5:41 AMInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 2,343 Shares of Stockmarketbeat.com - March 26 at 9:18 PMARS Pharmaceuticals (NASDAQ:SPRY) Reaches New 1-Year High at $9.75marketbeat.com - March 26 at 3:27 PMARS Pharmaceuticals (NASDAQ:SPRY) Sees Large Volume Increasemarketbeat.com - March 25 at 1:34 PMBuy Rating on ARS Pharmaceuticals Amid Strong neffy Approval Prospects and Indication Expansionmarkets.businessinsider.com - March 25 at 4:50 AMRichard E. Lowenthal Sells 1,918 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stockinsidertrades.com - March 22 at 10:48 AMInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Sells 1,918 Shares of Stockmarketbeat.com - March 21 at 10:19 PMARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Resultsfinance.yahoo.com - March 21 at 6:30 PMARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 21 at 4:05 PMARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 4.9%marketbeat.com - March 19 at 3:09 PMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Sells $25,200.00 in Stockinsidertrades.com - March 16 at 11:14 AMInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Sells 2,800 Shares of Stockmarketbeat.com - March 15 at 10:54 PMARS Pharmaceuticals (NASDAQ:SPRY) Rating Reiterated by Wedbushmarketbeat.com - March 11 at 12:19 PMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Fmr LLCmarketbeat.com - March 10 at 4:24 AMARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Dayglobenewswire.com - March 7 at 4:05 PMARS Pharmaceuticals, Inc. to Post FY2023 Earnings of ($0.61) Per Share, Leerink Partnrs Forecasts (NASDAQ:SPRY)marketbeat.com - March 7 at 6:40 AMARS Pharmaceuticals just upgraded at Leerink, here's whyrealmoney.thestreet.com - March 6 at 4:30 PMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by RA Capital Management L.P.marketbeat.com - March 6 at 2:35 PMARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024globenewswire.com - March 6 at 9:01 AMARS Pharmaceuticals (NASDAQ:SPRY) Upgraded to Outperform at Leerink Partnrsmarketbeat.com - March 6 at 7:27 AMARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up to $8.65marketbeat.com - March 5 at 12:42 PMSVB Leerink Upgrades ARS Pharmaceuticals (NASDAQ:SPRY) to Outperformmarketbeat.com - March 5 at 7:50 AMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Richard E. Lowenthal Sells 3,782 Sharesmarketbeat.com - March 1 at 10:16 PMARS Pharma's Neffy Shows Rapid Symptom Control In Phase 2 Urticaria Clinical Studymarkets.businessinsider.com - February 26 at 12:39 PMARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical studyglobenewswire.com - February 26 at 9:01 AMARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 7.5%marketbeat.com - February 23 at 1:59 PMLeerink Partnrs Analysts Lower Earnings Estimates for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)marketbeat.com - February 23 at 8:21 AMARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024globenewswire.com - February 22 at 9:01 AMHold Rating Maintained for ARS Pharmaceuticals Amid FDA Approval Process and Commercialization Concernsmarkets.businessinsider.com - February 22 at 7:48 AMLoss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Termfinance.yahoo.com - February 22 at 7:48 AM Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Thousands of investors use this no cost solution | Do you? (Ad)In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media. Simply tap here now to subscribe and start getting "Insider Financial Advantage" SPRY Media Mentions By Week SPRY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRY News Sentiment▼0.320.44▲Average Medical News Sentiment SPRY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRY Articles This Week▼62▲SPRY Articles Average Week Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ETNB News Today SAVA News Today ZNTL News Today INVA News Today ABVX News Today OPK News Today SAGE News Today ARCT News Today PLRX News Today ARQT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRY) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
